Literature DB >> 11870823

Statistical approaches to establishing vaccine safety.

Vladimir Dragalin1, Valerii Fedorov, Brigitte Cheuvart.   

Abstract

In a vaccine safety trial, the primary interest is to demonstrate that the vaccine is sufficiently safe, rejecting the null hypothesis that the relative risk of an adverse event attributable to the new vaccine is above a prespecified value, greater than one. We evaluate the exact probability of type I error of the likelihood score test, with sample size determined by normal approximation, by enumeration of the binomial outcomes in the rejection region and show that it exceeds the nominal level. In the case of rare adverse events, we recommend the Poisson approximation as an alternative and develop the corresponding conditional and unconditional tests. We give sample size and power calculations for these tests. We also propose optimal randomization strategies which either (i) minimize the total number of adverse cases or (ii) minimize the expected number of subjects when the vaccine is unsafe. We illustrate the proposed methods using a hypothetical vaccine safety study. Copyright 2002 John Wiley & Sons, Ltd.

Mesh:

Substances:

Year:  2002        PMID: 11870823     DOI: 10.1002/sim.1039

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  4 in total

1.  Efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine in Chinese women aged 18-25 years: event-triggered analysis of a randomized controlled trial.

Authors:  Feng-Cai Zhu; Shang-Ying Hu; Ying Hong; Yue-Mei Hu; Xun Zhang; Yi-Ju Zhang; Qin-Jing Pan; Wen-Hua Zhang; Fang-Hui Zhao; Cheng-Fu Zhang; Xiaoping Yang; Jia-Xi Yu; Jiahong Zhu; Yejiang Zhu; Feng Chen; Qian Zhang; Hong Wang; Changrong Wang; Jun Bi; Shiyin Xue; Lingling Shen; Yan-Shu Zhang; Yunkun He; Haiwen Tang; Naveen Karkada; Pemmaraju Suryakiran; Dan Bi; Frank Struyf
Journal:  Cancer Med       Date:  2016-12-20       Impact factor: 4.452

2.  Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.

Authors:  Jerald Sadoff; Glenda Gray; An Vandebosch; Vicky Cárdenas; Georgi Shukarev; Beatriz Grinsztejn; Paul A Goepfert; Carla Truyers; Hein Fennema; Bart Spiessens; Kim Offergeld; Gert Scheper; Kimberly L Taylor; Merlin L Robb; John Treanor; Dan H Barouch; Jeffrey Stoddard; Martin F Ryser; Mary A Marovich; Kathleen M Neuzil; Lawrence Corey; Nancy Cauwenberghs; Tamzin Tanner; Karin Hardt; Javier Ruiz-Guiñazú; Mathieu Le Gars; Hanneke Schuitemaker; Johan Van Hoof; Frank Struyf; Macaya Douoguih
Journal:  N Engl J Med       Date:  2021-04-21       Impact factor: 176.079

3.  The design and analysis of vaccine trials for COVID-19 for the purpose of estimating efficacy.

Authors:  Stephen Senn
Journal:  Pharm Stat       Date:  2022-07       Impact factor: 1.234

4.  Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18-25 years: results from a randomized controlled trial.

Authors:  Feng-Cai Zhu; Wen Chen; Yue-Mei Hu; Ying Hong; Juan Li; Xun Zhang; Yi-Ju Zhang; Qin-Jing Pan; Fang-Hui Zhao; Jia-Xi Yu; Yan-Shu Zhang; Xiaoping Yang; Cheng-Fu Zhang; Haiwen Tang; Helen Zhang; Marie Lebacq; Marie-Pierre David; Sanjoy K Datta; Frank Struyf; Dan Bi; Dominique Descamps
Journal:  Int J Cancer       Date:  2014-05-20       Impact factor: 7.396

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.